Medical Developments International Ltd (ASX: MVP) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Medical Developments International Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $34.95 million
P/E Ratio 1,000.00
Dividend Yield 0.00%
Shares Outstanding 86.31 million
Earnings per share -0.226
Dividend per share 0.04
Year To Date Return -47.37%
Earnings Yield 0.10%
Franking 100%
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Medical Developments International Ltd (ASX: MVP)
    Latest News

    Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
    Share Gainers

    These 4 small ASX shares are already up more than 19% in 2024!

    The All Ords remains in the red for 2024, but these four ASX shares have been rocketing higher.

    Read more »

    A young man working from home sits at his home office desk holding a cup of tea and looking out the window
    Small Cap Shares

    Buy these small cap ASX shares in September: Bell Potter

    These small caps could have major upside potential according to one broker.

    Read more »

    A doctor in a white coat with a stethoscope around his neck stands in the hallway of a hospital deep in concentration over a tablet device in his hands.
    Earnings Results

    Medical Developments share price leaps 5% on FY22 revenue boost

    The company said sales continued to be disrupted in FY22 due to the impacts from COVID.

    Read more »

    A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
    Share Fallers

    Why Alliance, Aurizon, MVP, and Suncorp shares are dropping today

    These ASX shares are out of form on Monday...

    Read more »

    A person plunges into the pool with only their feet visible above the surface, diving through a heart-shaped inflatable ring.
    Share Fallers

    Here's why the Medical Developments share price is sinking 17% on Monday

    The share has caught sellers attention today.

    Read more »

    Woman holding out her hand, symbolising a trading halt.
    Healthcare Shares

    Medical Developments share price halted amid 'significant near-term opportunities'

    The company seeks to raise additional capital.

    Read more »

    a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
    Share Gainers

    Why Core Lithium, MVP, Rio Tinto, and South32 shares are rising today

    These ASX shares are on form on Wednesday...

    Read more »

    Rocket powering up and symbolising a rising share price.
    Healthcare Shares

    Why the Medical Developments International (ASX:MVP) share price is rocketing 32% higher

    It has been a good day for this healthcare share...

    Read more »

    A doctor in a white coat with a stethoscope around his neck stands in the hallway of a hospital deep in concentration over a tablet device in his hands.
    Earnings Results

    Medical Developments International (ASX:MVP) share price on watch as losses widen

    Medical Developments International has handed in its half year results...

    Read more »

    laboratory workers looking disappointed
    Healthcare Shares

    Medical Developments (ASX:MVP) share price hits new 52 week low

    The Medical Developments share price is continuing to struggle today.

    Read more »

    a doctor in white coat slumps against a window, head on hand, gazing down in dejection.
    Share Fallers

    Medical Developments (ASX:MVP) share price falls on $13 million loss

    Investors are selling their shares in the company after today's announcement.

    Read more »

    share price plummeting down
    Share Fallers

    Why Buddy, Evolution, Medical Dev International, & Whitefield are dropping

    These ASX shares aren't having a good finish to the week...

    Read more »

    Frequently Asked Questions

    Yes, Medical Developments International historically pays two fully franked dividends a year.

    Medical Developments International generally pays its dividends in April and October. 

    Medical Developments International Ltd listed on the ASX on 15 December 2003.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Mar 2020 $0.0200 100.00% Interim 17 Apr 2020
    03 Sep 2019 $0.0200 100.00% Final 04 Oct 2019
    07 Mar 2019 $0.0200 100.00% Interim 17 Apr 2019
    30 Aug 2018 $0.0200 100.00% Final 05 Oct 2018
    02 Mar 2018 $0.0200 100.00% Interim 13 Apr 2018
    31 Aug 2017 $0.0000 100.00% Final 06 Oct 2017
    03 Mar 2017 $0.0200 100.00% Interim 10 Apr 2017
    01 Sep 2016 $0.0200 100.00% Final 07 Oct 2016
    02 Mar 2016 $0.0200 100.00% Interim 08 Apr 2016
    02 Sep 2013 $0.0200 100.00% Final 11 Oct 2013
    27 Feb 2013 $0.0300 100.00% Interim 11 Apr 2013
    28 Feb 2012 $0.0300 100.00% Interim 11 Apr 2012
    31 Aug 2011 $0.0300 100.00% Final 10 Oct 2011

    MVP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Medical Developments International Ltd

    Medical Developments International Ltd (ASX: MVP) is an Australian- based pharmaceutical company. It manufactures and distributes pharmaceutical drugs covering pain management, asthma, and resuscitation, as well as medical and veterinary equipment.

    The company has three business units: pharmaceuticals, medical devices, and veterinary products. The majority of its revenue comes from its pharmaceuticals segment which produces and sells the pain relief drug Penthrox within Australia, New Zealand, and the United Kingdom, as well as some sales in other countries. 



    MVP Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Jun 2024 $0.41 $0.01 2.50% 175,198 $0.40 $0.41 $0.40
    20 Jun 2024 $0.40 $0.01 2.53% 65,432 $0.40 $0.40 $0.40
    19 Jun 2024 $0.40 $-0.01 -2.50% 197,155 $0.39 $0.41 $0.39
    18 Jun 2024 $0.40 $0.00 0.00% 183,010 $0.40 $0.41 $0.39
    17 Jun 2024 $0.40 $-0.01 -2.47% 59,101 $0.40 $0.42 $0.38
    14 Jun 2024 $0.41 $0.02 5.13% 194,259 $0.39 $0.42 $0.39
    13 Jun 2024 $0.39 $-0.01 -2.50% 117,997 $0.40 $0.41 $0.39
    12 Jun 2024 $0.40 $-0.01 -2.44% 50,059 $0.40 $0.42 $0.40
    11 Jun 2024 $0.41 $0.00 0.00% 64,876 $0.42 $0.42 $0.41
    07 Jun 2024 $0.41 $-0.04 -9.09% 192,660 $0.44 $0.45 $0.41
    06 Jun 2024 $0.44 $0.03 7.23% 99,468 $0.42 $0.44 $0.42
    05 Jun 2024 $0.42 $0.00 0.00% 182,755 $0.42 $0.43 $0.41
    04 Jun 2024 $0.42 $0.01 2.44% 115,091 $0.41 $0.43 $0.41
    03 Jun 2024 $0.41 $-0.02 -4.71% 214,300 $0.42 $0.43 $0.41
    31 May 2024 $0.43 $-0.01 -2.33% 68,148 $0.43 $0.43 $0.42
    30 May 2024 $0.43 $-0.05 -10.53% 210,767 $0.48 $0.48 $0.42
    29 May 2024 $0.48 $0.07 17.28% 226,896 $0.41 $0.49 $0.41
    28 May 2024 $0.41 $0.01 2.53% 228,605 $0.40 $0.42 $0.40
    27 May 2024 $0.40 $-0.01 -2.50% 120,010 $0.40 $0.41 $0.39
    24 May 2024 $0.40 $0.02 5.19% 110,942 $0.39 $0.40 $0.38
    23 May 2024 $0.39 $0.00 0.00% 92,029 $0.38 $0.40 $0.38

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    03 Apr 2024 Russell Basser Buy 15,873 $9,761
    On-market trade.
    07 Sep 2023 Gordon Naylor Buy 56,000 $49,559
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Leon Hoare Non-Executive Director Sep 2013
    Mr Hoare is the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously, he was Managing Director of Smith & Nephew ANZ (all divisions) until 2015, one of the Smith & Nephew's largest global subsidiaries outside the USA. He served as President of Smith & Nephew's Asia Pacific Advanced Wound Management (AWM) business for 5 years and was a member of the Global Executive Management for the AWM Division. In his 24 years with Smith & Nephew, he also held roles in Marketing, Divisional and General Management. His career has also included a senior role at Bristol Myers Squibb (medical devices), and as Vice Chair of the board of Australia's peak medical device industry body, Medical Technology Association of Australia. Mr Hoare is also the chair of the Human Resources Committee.
    Mr Richard Betts Non-Executive Director May 2021
    Mr Betts is an experienced executive who has held senior roles with ASX listed entities over 20 years. His previous roles with multiple listed companies has provided a deep understanding of working in various jurisdictions, including North America, Europe and Asia. Mr Betts has extensive financial and governance experience within international manufacturing environments. Mr Betts is Chair of the Audit and Risk Committee and a member of Continuous Disclosure Committee.
    Ms Maria (Mary) Elisabeth Sontrop Non-Executive Director Mar 2021
    Ms Sontrop has extensive international experience in the biopharmaceutical sector across manufacturing operations, quality, and business integration. During her 28 years with CSL Limited, Ms Sontrop was a part of CSL's globalisation through a series of major acquisitions. This included primary responsibility for the turnaround of unprofitable manufacturing operations. Subsequently as head of global plasma manufacturing, Ms Sontrop delivered a globally integrated manufacturing network spanning four countries. As head of CSL's Australia and New Zealand pharmaceutical business, Ms Sontrop and her team delivered Australia's most successful adolescent/adult immunisation program and achieved USFDA (US Food & Drug Administration) approval to manufacture and export CSL's seasonal and pandemic influenza vaccines. Ms Sontrop also has international governance experience. She is a member of Audit and Risk Committee.
    Ms Christine Emmanuel-Donnelly Non-Executive Director May 2020
    Ms Emmanuel-Donnelly is an experienced IP and business development professional having 35 years of experience locally and internationally. She was previously Vice President of the Institute of Patent & Trademarks Attorneys of Australia for over 2 years. She is a member of Audit and Risk Committee.
    Mr Gordon Naylor Non-Executive DirectorNon-Executive Chairman Oct 2020
    Mr Naylor has enjoyed a long and successful international business career. For over 30 years he was a key part of the internationalisation of CSL, holding a range of business and functional leadership roles including Chief Financial Officer. He is also a member of the Human Resources Committee and Continuous Disclosure
    Dr Russell Basser Non-Executive Director Aug 2023
    Dr Basser has 30 years of international medical and biopharmaceutical experience. Dr Bassers worked as a medical oncologist in Melbourne prior to joining CSL in 2001. During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has substantial expertise in international drug and vaccine development and spent several years based in the USA. Dr Basser currently serves as a non-executive director on the Boards of Starpharma Holdings Limited and Doherty Clinical Trials. He has previously served on the Board of the ANZ Breast Cancer Trials Group and the Hadassah Australia Medical Research Collaboration.
    Mr Brent MacGregor Chief Executive Officer Nov 2020
    Ms Tara Eaton Company SecretaryGeneral Counsel Aug 2022
    Brent MacGregor Chief Executive Officer
    Tara Eaton Company SecretaryGeneral Counsel

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 9,743,442 11.29%
    Lawn Views Pty Ltd <Angela Williams Family A/C> 5,904,120 6.84%
    P Morgan Nominees Australia Pty Limited 3,444,174 3.99%
    Moggs Creek Pty Ltd <Moggs Creek Super A/C> 2,905,320 3.37%
    Netwealth Investments Limited <Wrap Services A/C> 2,731,071 3.16%
    Citicorp Nominees Pty Limited 1,726,027 2.00%
    Dr Russell Kay Hancock 1,714,214 1.99%
    Kidder Peabody Pty Ltd 1,042,945 1.21%
    Ubs Nominees Pty Ltd 1,040,936 1.21%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 1,001,569 1.16%
    Mr David Williams <William Street A/C> 861,817 1.00%
    Payne Media Pty Ltd 860,147 1.00%
    Neweconomy Com Au Nominees Pty Limited <900 Account> 762,881 0.88%
    Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 682,749 0.79%
    Naylor-Stewart Investments Pty Ltd <Naylor-Stewart Family A/C> 645,167 0.75%
    Mr Alistair David Strong 630,000 0.73%
    Mrs Virginia Catherine Hancock 618,487 0.72%
    National Nominees Limited 524,026 0.61%
    Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 502,548 0.58%
    Norman Chan Pty Ltd <Blue Elephant Family A/C> 450,000 0.52%